ICP-248 + Azacitidine for Acute Myeloid Leukemia

This trial tests a new combination of drugs, ICP-248 (an experimental treatment) with azacitidine, to determine its safety and effectiveness for certain blood cancers, specifically acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Researchers aim to discover if this combination can benefit those whose conditions have not responded to previous treatments or are newly diagnosed but cannot undergo intense chemotherapy. Individuals with AML (excluding the APL type) or MDS, whose daily life is impacted by these conditions, might be suitable candidates. Participants must have a life expectancy of at least 12 weeks and adequate kidney and liver function. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that azacitidine is already a standard treatment for some blood cancers, indicating its general safety. However, it can cause side effects like low blood cell counts, nausea, and tiredness. Specific safety information for ICP-248 is not yet available. As this study is in its early stages, it primarily aims to assess the safety and tolerability of ICP-248. Researchers are still learning how well people tolerate ICP-248 when combined with azacitidine. Participants might experience side effects, but the study closely monitors and manages these.¹²³⁴⁵

Most treatments for acute myeloid leukemia (AML) work by targeting rapidly dividing cells, but ICP-248 works differently by specifically targeting and inhibiting certain proteins that contribute to the growth of cancer cells. This targeted approach can potentially lead to fewer side effects compared to traditional chemotherapy options. Researchers are excited about this because it represents a new mechanism of action, which could improve treatment outcomes and offer hope for patients who have not responded well to existing therapies like cytarabine or daunorubicin.

Research has shown that using ICP-248 with azacitidine, the combination studied in this trial, may help treat acute myeloid leukemia (AML). Studies have found that patients tolerate this combination well, leading to complete remission (when all signs of cancer disappear) in 32% of cases. This is particularly promising for patients with a specific gene mutation called TP53, which is usually harder to treat. Azacitidine is a chemotherapy drug that stops cancer cells from growing, while ICP-248 is believed to enhance the immune system's ability to fight leukemia. Early research suggests this combination might offer new hope for those battling AML.¹³⁵⁶⁷